46
Participants
Start Date
August 31, 2008
Primary Completion Date
April 30, 2009
Study Completion Date
January 31, 2011
cediranib (RECENTIN TM, AZD2171)
20 mg cediranib once daily from Days 1 to 7; then 20 mg cediranib plus 400 mg ketoconazole from Days 8-10; then 20 mg cediranib once daily from Days 11-23. At Day 24 patients may dose escalate to 30 mg tablet once daily providing the treatment is well tolerated (this may be escalated up to 45 mg if the 30mg dose is tolerated for a minimum of 14 days)
Research Site, Hamilton
Research Site, Toronto
Research Site, Vancouver
Research Site, Copenhagen
Research Site, Herlev
Lead Sponsor
AstraZeneca
INDUSTRY